Mycoplasma Testing Market Share

North American Market Statistics

The North America mycoplasma testing market is poised to be the largest with a share of about 37% by the end of 2035. The presence of various biotech and pharmaceutical companies and increased investment in R&D will push the formation of new drugs and antibodies, recombinant proteins, and cell-based therapies. The need for mycoplasma testing increases correspondingly to ensure the safety and quality of these products. The Department of Health and Human Services in the United States will put USD 40 million to broaden the role of biomanufacturing in the development of active pharmaceutical ingredients (APIs), antibiotics, and essential pharmaceuticals.

APAC Market Analysis

The Asia Pacific mycoplasma testing market is estimated to be the second largest, registering a share of about 26% over the forecast period. The increased knowledge of the effects of infectious substances, as well as regulatory restrictions enforced by healthcare organizations to improve biosafety quality, are driving the demand for mycoplasma testing. WHO's Regional Office for South East Asia (SEARO) arranged two regional trainings to assist biosafety, concentrating on infectious material shipping, and bio-risk assessment.

European Market Forecast

Further, the mycoplasma testing market in Europe is projected to hold a notable share between 2023 and 2035. The market growth in the region is due to strict adherence to good laboratory practices (GLP), and good manufacturing practices (GMP) by all the biotech and pharma companies. Hence, mycoplasma testing is considered an essential component of these practices to ensure product safety.

Frequently Asked Questions (FAQ)

Increasing expenditure on new biotech research, advancing technology of mycoplasma testing, and globalization of research are the major factors driving the market growth.

The market size of mycoplasma testing is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 â€“ 2035.

T he major players in the market are Thermo Fisher Scientific, Inc, Merck KGaA,, Lonza Group Ltd., PromoCell GmbH, Asahi Kasei Corporation, Sartorius AG, InvivoGen, Eurofins Scientific, SwiftDx, and Agathos Biologics.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by application, technique, product & services, end user.

The cell line segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Lack of skilled workers and high cost of testing are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Mycoplasma Testing Market Share